Literature DB >> 18778592

The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes.

Osama Hamdy1, Catherine Carver.   

Abstract

Targeting body weight, as an alternative model to targeting hemoglobin A(1c), is emerging as a viable and potentially cost-effective approach to diabetes management in clinical practice. Why WAIT (Weight Achievement and Intensive Treatment) is a 12-week multidisciplinary program for weight control and intensive diabetes management specifically designed for application in routine diabetes practice. The program, which is generally covered by insurance, is followed by continuous support aimed at long-term maintenance of weight loss and diabetes control. This model was effective in improving key metabolic abnormalities observed in diabetic patients. Eighty-two percent of participants achieved the target hemoglobin A(1c) of less than 7% on less diabetes medications. The achieved weight reduction after 12 weeks of intervention was maintained for an additional year. Future dissemination of this intervention model in routine clinical practice may require wider endorsement by third-party payers and support of governmental health care agencies to halt the progression of the epidemic of obesity and diabetes in the United States.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778592     DOI: 10.1007/s11892-008-0071-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  30 in total

1.  Prevalence of the metabolic syndrome among US middle-aged and older adults with and without diabetes--a preliminary analysis of the NHANES 1999-2002 data.

Authors:  Susan X Lin; E Xavier Pi-Sunyer
Journal:  Ethn Dis       Date:  2007       Impact factor: 1.847

2.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

Review 3.  Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.

Authors:  Reinhard H A Becker; Annke D Frick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  Effectiveness of weight loss in the elderly with type 2 diabetes mellitus.

Authors:  C J Hsieh; P W Wang
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

5.  Influence of resistance exercise training on glucose control in women with type 2 diabetes.

Authors:  L M Fenicchia; J A Kanaley; J L Azevedo; C S Miller; R S Weinstock; R L Carhart; L L Ploutz-Snyder
Journal:  Metabolism       Date:  2004-03       Impact factor: 8.694

6.  Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Authors:  Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski
Journal:  Diabetes Care       Date:  2007-03-15       Impact factor: 19.112

7.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.

Authors:  I J Hickman; J R Jonsson; J B Prins; S Ash; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

8.  Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.

Authors:  R R Henry; B Gumbiner; T Ditzler; P Wallace; R Lyon; H S Glauber
Journal:  Diabetes Care       Date:  1993-01       Impact factor: 19.112

9.  Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition.

Authors:  Mary C Gannon; Frank Q Nuttall
Journal:  Nutr Metab (Lond)       Date:  2006-03-23       Impact factor: 4.169

10.  A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Authors:  J Rosenstock; M Davies; P D Home; J Larsen; C Koenen; G Schernthaner
Journal:  Diabetologia       Date:  2008-01-16       Impact factor: 10.122

View more
  28 in total

1.  Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Authors:  Su-Ann Ding; Donald C Simonson; Marlene Wewalka; Florencia Halperin; Kathleen Foster; Ann Goebel-Fabbri; Osama Hamdy; Kerri Clancy; David Lautz; Ashley Vernon; Allison B Goldfine
Journal:  J Clin Endocrinol Metab       Date:  2015-04-24       Impact factor: 5.958

2.  Nonsurgical diabetes weight management: be prepared for sustainable and practical interventions.

Authors:  Osama Hamdy
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

3.  Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial.

Authors:  Florencia Halperin; Su-Ann Ding; Donald C Simonson; Jennifer Panosian; Ann Goebel-Fabbri; Marlene Wewalka; Osama Hamdy; Martin Abrahamson; Kerri Clancy; Kathleen Foster; David Lautz; Ashley Vernon; Allison B Goldfine
Journal:  JAMA Surg       Date:  2014-07       Impact factor: 14.766

Review 4.  Protein content in diabetes nutrition plan.

Authors:  Osama Hamdy; Edward S Horton
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

5.  ASGE EndoVators Summit: defining the role and value of endoscopic therapies in obesity management.

Authors:  Marvin Ryou; Kenneth R McQuaid; Christopher C Thompson; Steven Edmundowicz; Klaus Mergener
Journal:  Surg Endosc       Date:  2017-11-14       Impact factor: 4.584

6.  ASGE EndoVators Summit: Defining the Role and Value of Endoscopic Therapies in Obesity Management.

Authors:  Marvin Ryou; Kenneth R McQuaid; Christopher C Thompson; Steven Edmundowicz; Klaus Mergener
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

7.  ASGE EndoVators Summit: Defining the Role and Value of Endoscopic Therapies in Obesity Management.

Authors:  Marvin Ryou; Kenneth R McQuaid; Christopher C Thompson; Steven Edmundowic; Klaus Mergener
Journal:  J Gastrointest Surg       Date:  2017-11-14       Impact factor: 3.452

8.  Lifestyle interventions for the treatment of class III obesity: a primary target for nutrition medicine in the obesity epidemic.

Authors:  George L Blackburn; Samuel Wollner; Steven B Heymsfield
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

9.  Higher protein intake is associated with increased risk for incident end-stage renal disease among blacks with diabetes in the Southern Community Cohort Study.

Authors:  R Malhotra; K L Cavanaugh; W J Blot; T A Ikizler; L Lipworth; E K Kabagambe
Journal:  Nutr Metab Cardiovasc Dis       Date:  2016-07-21       Impact factor: 4.222

10.  Anti-inflammatory nutrition as a pharmacological approach to treat obesity.

Authors:  Barry Sears; Camillo Ricordi
Journal:  J Obes       Date:  2010-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.